Clinical Trials Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jan 14, 2015; 21(2): 600-608
Published online Jan 14, 2015. doi: 10.3748/wjg.v21.i2.600
Table 1 Medications used by the patients only at follow-up
DrugPatients (n)
Antacids1
Neuroleptic drug1
Drug against neuropathic pain1
Anti epileptic drug1
Acetaminophen3
Antidepressant3
B12 vitamine3
Post climacteric hormone1
Anticonceptive2
NSAIDs2
Sedative1
Table 2 Irritable bowel syndrome quality of life at baseline and at follow-up
DimensionBaselineFollow-upP value
Emotional functioning56 (31-88)69 (44-100)0.001
Mental health80 (50-100)90 (45-100)NS
Sleep67 (33-100)83 (42-100)0.008
Energy50 (38-88)75 (50-100)0.005
Physical functioning67 (33-100)92 (49-100)0.002
Diet60 (47-87)73 (40-93)NS
Social role69 (43-94)81 (50-100)0.009
Physical role69 (31-100)81 (38-100)NS
Sexual relations60 (18-80)60 (20-80)NS
Table 3 Short form 36 at baseline and at follow-up
SubscaleBaselineFollow-upP value
Physical functioning90 (65-100)95 (64-100)NS
Physical role50 (0-100)100 (0-100)NS
Bodily pain51 (31-84)51 (22-100)NS
General health perceptions54 (25-83)67 (32-97)0.006
Vitality45 (20-80)55 (25-85)NS
Social functioning75 (38-100)75 (49-100)NS
Emotional role67 (0-100)100 (0-100)0.027
Mental health72 (32-92)74 (52-96)0.016
Table 4 Short form 36 at the end of intervention and at follow-up
SubscaleEnd of interventionFollow-upP value
Physical function90 (47-100)95 (56-100)NS
Physical role75 (0-100)100 (0-100)NS
Bodily pain51 (26-72)61 (22-100)0.030
General health perceptions60 (22-85)63 (30-97)0.013
Vitality45 (15-78)55 (22-83)0.012
Social function75 (43-100)88 (50-100)NS
Emotional role100 (0-100)100 (0-100)NS
Mental health64 (35-92)76 (52-94)0.006